-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Capturing the attention of investors: What is the value of your approach?
Jul 25, 2018
Persuading investors of your product's value involves a balancing act between the importance of cost, time, risk and commercial return.
As an emerging biopharma, you have selected your candidate and articulated your product vision through the creation of a target product profile – so you know where you are going. You have planned your development pathway, balancing time, cost, and risk at specific decision points – so you know how you are getting there. Both steps are vital in capturing the attention of investors, and have been outlined in the first two blogs in the series.
This post (3rd of 3) takes you to the next level by helping you to optimize and demonstrate the value of your approach. Creating an early and accurate forecast model; understanding time, cost, risk, and revenue in more detail; and valuing your program in terms of risk-adjusted or expected net present value (eNPV) will all be critically important when convincing key stakeholders to join you.
Creating a single, unifying metric: Expected net present value
There are several key variables that you need to be aware of in the process of optimizing your drug development approach:
- Cost: Development and commercial costs
- Time: Critical path duration of the plan
- Risk: Probability of technical success
- Commercial return: Potential market share and revenue
Expected net present value (eNPV) is a robust methodology that provides a convincing way to weigh different approaches. Using eNPV as a unifying metric means that you can compare different molecules, indications, or design decisions and see the impact of trade-offs. For example, you might evaluate the impact of changing potential market share and revenue by looking at a different indication.
Emerging biopharma are under pressure to show value
While demonstrating value is important for any organization developing new drugs, the pressure is more acute for emerging biopharma companies. Emerging biopharma companies are smaller, have less cash in hand, and have a greater need for convincing investors at any given point in the drug development pathway.
Data-informed planning for robust decision-making
With access to the right data and domain knowledge, it is possible to understand the impact of various factors on crucial outputs.
|
Domain knowledge |
Trial design |
Development plan |
Key drivers of risk |
Market share analogues |
|
Data |
Development experience |
Clinical trials data |
Industry benchmarks |
Sales databases |
|
Outputs |
Costs |
Time |
Risk |
Commercial return |
While all the critical success factors are important, modeling the interplay between these factors can be challenging. For example, indications for rare diseases generally have a higher probability of success than higher-prevalence diseases but also a smaller pool of potential patients which may slow enrollment. Plans to offset with a higher price point can present a major conundrum for investors and ultimately for payers. New indications for proven drugs and biologics are more likely to succeed than new molecular entities, but may face much stiffer competition in the marketplace. Additionally, patient-centricity also plays a role although it may not be imperative for investors at an early stage.
Scenario generation and modelling can support choosing the best clinical design from among many options, allowing you to see what happens to eNPV, for example under conservative, standard and aggressive approaches to time and cost trade-offs.
The three blogs in the Capturing the attention of investors series have each taken a different part of the whole. The first, on ‘articulating your product vision’, looked at the importance of understanding business drivers and ensuring their alignment with product goals. The second, on ‘choosing the right development path’, explored design decisions, alternatives and trade-offs. And this, the third, ‘the value of your approach’, focused on optimizing cost, time, risk and/or commercial return. These three together should put you, as an emerging biopharma company, on the road to success.
To hear experts talk in more depth and listen to them answer audience questions, go to Capturing the attention of investors for the recorded webinar, supported by a slide presentation.
More about the Author:
- Bruce Basson
Senior Scientific Advisor
Bruce has worked as a biostatistician in the pharmaceutical industry for over 20 years across numerous therapeutic areas. One of his areas of expertise is leading development teams through scientific evidence generation plan strategy and optimization workshops. He is also a specialist in technical due diligence and asset value estimation using net present value.
Contributor:
- Tara Rheault, Ph.D., MPH
Senior Therapeutic Strategy Director, Drug Development Lead
Tara Rheault has over 16 years of cross-functional leadership experience across drug discovery and development. Dr. Rheault started her career as a medicinal chemist at GlaxoSmithKline where she was the inventor of the now marketed drug Tafinlar. Dr. Rheault then moved on to global project leadership for early development projects, including portfolio and governance management. She then transitioned into late stage clinical development as a clinical program and study leader. Dr. Rheault has continued to build her expertise at IQVIA in the development of integrated commercial and R&D strategies, helping clients articulate their differentiated value story along with a robust plan to achieve their product goals.